Compare EPR Properties (EPR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Novo Nordisk A/S — how do they compare? EPR Properties trades at $55.08 (market cap $4.17B), while Novo Nordisk A/S trades at $38.48 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 39.6× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and Novo Nordisk A/S for 116 Days on average.
| EPR | NVO | |
|---|---|---|
Market Cap | $4.17B | $165.31B |
Volume | 992,716 | 11,432,838 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $63.98 |
52-Week Low | $48.71 | $35.29 |
Typical Hold Time | 46 Days | 116 Days |
Enterprise Value | $7.68B | $179.56B |
Dividend Yield | 6.84% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $55.03, up 1.76% today, with a bearish technical signal but oversold RSI suggesting potential reversal. The REIT reported strong Q2 2026 EPS beat ($0.79 vs. $0.745 expected) and maintains a high gross margin of 91.41%. Recent news highlights its 6.5% dividend yield and diversification into theme parks and experiential properties, though 2026 net income is projected to decline to $263 million.
The stock offers value with a forward P/E of 17.44 and consensus price target of $65.50, implying 19% upside. Key risks include declining 2026 profitability, high leverage exposure, and sensitivity to interest rates. Analyst sentiment is mixed with 32% buy ratings, but institutional buying and oversold conditions support a cautious bullish outlook for income-focused investors.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
